Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

APRI 1.91 -0.01 (-0.78%)
price chart
Taglich Brothers Initiates Coverage on Apricus Biosciences, Inc.
Apricus Biosciences, Inc., (NASDAQ: APRI) headquartered in San Diego, California, manufactures a treatment for erectile dysfunction and is developing pharmaceuticals to treat urological and rheumatoid disorders, and women's sexual disorders.
Price Target Update on Apricus Biosciences Inc  Stafford Daily
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
First Call Rating Update on Apricus Biosciences, Inc
Apricus Biosciences, Inc (NASDAQ:APRI) has been rated as Buy in the consensus report of First Call Corporation. The rating of the company was disclosed in the equity research recommendation.
Apricus Biosciences Announces Corporate Update and Fourth Quarter and Year ...
Apricus Biosciences, Inc. APRI, -2.67% a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Monday, March ...
Company Shares of Apricus Biosciences, Inc Rally 11.82%  Wall Street Pulse
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)
SAN DIEGO, Jan. 27, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, announced that today, January 27, 2015, the United States Patent and ...
Apricus Bio up on issuance of patent (APRI)  Seeking Alpha (registration)
Apricus Biosciences (APRI) Gains After Announcing Patent for Treating ...  StreetInsider.com
Apricus Biosciences Expands Exclusive License Agreement With an Existing ...
SAN DIEGO, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive license ...
Apricus Biosciences (APRI) Gains After Announcing Expanded License ...  StreetInsider.com
Will Apricus Biosciences (APRI) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Apricus Biosciences Inc (APRI - Snapshot Report). The stock has moved higher by 13.6% in the past month, while it is also above its 20 Day SMA too.
Apricus closes direct equity offering (APRI)
Apricus Biosciences (NASDAQ:APRI) secures a direct offering of 6,043,955 shares of common stock and warrants to purchase up to 3,021,977 shares of stock with Sarissa Capital Management LP and an additional accredited investor.
Apricus Biosciences Announces $11 Million Registered Direct Offering With ...  GlobeNewswire (press release)
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Brian T. Dorsey as the Company's ...
Related articles »